The TBnet registry is a multinational, prospective tuberculosis registry established by the Tuberculosis Network European Trialsgroup (TBnet e.V.) to collect and analyze long-term data from TB patients across Europe. Its purpose is to centralize data on TB epidemiology, prevention, diagnosis, and treatment to improve care, support research, and ultimately help eliminate TB. The registry captures risk factors, diagnostic details (e.g., microbiology, imaging, drug resistance), treatment data, side effects, outcomes, and late complications.
In Western Europe, however, tuberculosis is a rare disease, and individual clinics see only small numbers of patients. For clinical research on the epidemiology, prevention, diagnosis, and treatment of tuberculosis, it is therefore essential that patient data are collected and analyzed in a centralized manner. This allows for the adequate inclusion of at-risk groups and studying less common forms of tuberculosis (e.g., multidrug-resistant tuberculosis, extrapulmonary tuberculosis). Hence, the Tuberculosis Network European Trialsgroup TBnet e.V., aims to establish a tuberculosis registry in which long-term datasets from TB patients across Europe will be stored. The findings obtained from the tuberculosis registry will make an important contribution to combating and ultimately eliminating TB. TBnet is a pan-European clinical research network dedicated to improving the diagnosis, treatment, and prevention of tuberculosis and related mycobacterial diseases. Founded in 2006, TBnet brings together clinicians, scientists, and public health experts from more than 30 countries. The network has established large collaborative cohorts and conducts multicenter clinical studies, registries, and consensus projects that have shaped international TB guidelines. The TBnet Steering Committee will serve as data access committee: Research questions/data inquiries will be submitted to the TBnet Steering Committee through a structured process on the TBnet website and are approved only after internal and external peer review (as outlined in the TBnet statutes).
Study Type
OBSERVATIONAL
Enrollment
1,000
Prospective data collection in a clinical data registry
Research Center Borstel, Leibniz Lung Center
Borstel, Schleswig-Holstein, Germany
IRCCS Ospedale Sacro Cuore Don Calabria
Negrar, Verona, Italy
Extrapulmonary TB: Favourable treatment outcome
Identification of parameters that predict/are significantly associated with favorable outcome in EPTB
Time frame: December 2040
Drug-resistant TB: Description of treatment outcome
Percentage of patients cured, failed, died, under/after therapy according to WHO and TBnet outcome criteria
Time frame: December 2040
Drug-resistant TB: Description of treatment completion
Percentage of patients who develop serious/severe drug-related adverse events/who have to change regimen due to drug-related adverse events
Time frame: December 2040
Drug-susceptible TB: Mortality risk score
Development of a TB mortality risk score, defined by a final set of predictors and a weighted scoring system based on routine clinical, radiological, microbiological, and laboratory data.
Time frame: December 2040
Therapeutic drug monitoring: Description of Pharmacokinetics
Summary of pharmacokinetic parameters: Mean max/min concentrations, number of patients that are over-/under-/correctly dosed
Time frame: December 2040
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.